LCA3 siRNA Oligos set (Human)

Cat. No.
4 x 5 nmol

Lead Time
3 to 4 weeks
Cat. No. 61125171
Name LCA3 siRNA Oligos set (Human)
Unit 4 x 5 nmol
Gene Name LCA3
Species Human
System siRNA oligos
Target Sequence Sequence available upon placing order
Storage Condition Upon receipt, -70°C for long term storage; -20°C for short term storage.
Recommended storage concentration is above 20μM.
After reconstitution, store in aliquots to avoid repeated freeze-thawing.
Disclaimer 1. Disclaimer for accession number: The provided accession number refers to the transcript (mRNA) sequence the siRNA product targets. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 2. Disclaimer for intended use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 3. Disclaimer for extra nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct.
Guarantee abm guarantees that at least one out of the three siRNA oligos purchased in a set will result in over 70% knockdown of gene expression (qPCR) within target cells showing >50% transfection efficiency. If this is not the case, we will provide a one-time replacement of three new constructs with alternative siRNA sequences. To qualify for this replacement, the oligos must be transfected at the appropriate amounts (see Troubleshooting section of the User Manual) and assayed at least 48 hours post-transfection. Customers must provide adequate data to show >50% transfection efficiency with a positive control, plus additional qPCR data to evaluate the level of gene expression. The replacement set will not covered by the same guarantee, and if these constructs are also considered to be ineffective then it is most likely the gene is not susceptible to siRNA knockdown. abm limits its obligation and liability for the success of this technology to providing one replacement of any siRNA oligo product only. Before sending your inquiry, please make sure you have optimized your experiments as far as possible, this includes (where applicable) optimizing the siRNA concentration and the duration of transfection (up to 72 hours). Please send all replacement inquiries and experimental data to  [email protected]
Caution This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information.

Free controls included with every siRNA oligo order:
1 x 2.5nmol (1 OD duplex) of positive control siRNA
1 x 2.5nmol (1 OD duplex) of negative control siRNA
1 x 2.5nmol (1 OD duplex) of FAM-labeled negative control siRNA

Reconstitution Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For example, resuspend one tube of 2.5 nmol (1 OD) siRNA oligo in 125µl of DEPC water to get a final concentration of 20µM. Please note that negative controls will only require half the amount of DEPC water for resuspension because there is only 1.25 nmol (0.5 OD) in each tube
Material Citation If use of this material results in a scientific publication, please cite the material in the following manner: Applied Biological Materials Inc, Cat. No. 61125171
Print & Download Datasheet
  • Liang, Y., Song, X., Li, Y., Su, P., Han, D., Ma, T., … Yang, Q. "circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer" Oncogene 38(42):6850–6866 (2019). DOI: 10.1038/s41388-019-0926-z.
  • Verma, M., Asakura, Y., & Asakura, A. "Inhibition of microRNA‐92a increases blood vessels and satellite cells in skeletal muscle but does not improve duchenne muscular dystrophy–related phenotype in mdx mice" Muscle & Nerve 59(5):594–602 (2019). DOI: 10.1002/mus.26433.
  • Wu., Chien-Wei., . "Downregulation of MiR-144 by Triptolide Enhanced p85α−PTEN Complex Formation Causing S Phase Arrest of Human Nasopharyngeal Carcinoma Cells" European Journal of Pharmacology 855:137-148 (2019). DOI: 10.1016/j.ejphar.2019.04.052..
  • Wu, M.-J., Chen, Y.-S., Kim, M. R., Chang, C.-C., Gampala, S., Zhang, Y., … Chang, C.-J. "Epithelial-Mesenchymal Transition Directs Stem Cell Polarity via Regulation of Mitofusin" Cell Metabolism 29(4):993–1002.e6 (2019). DOI: 10.1016/j.cmet.2018.11.004.
  • Xiang, X., Zhou, Y., Sun, H., Tan, S., Lu, Z., Huang, L., & Wang, W. "Ivabradine abrogates TNF-α-induced degradation of articular cartilage matrix" International Immunopharmacology 66:347–353 (2019). DOI: 10.1016/j.intimp.2018.11.035.
  • Zhou, Y., Lei, J., Xie, Q., Wu, L., Jin, S., Guo, B., ... & Zhang, J. "Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5" Science Advances 5(11):eaax0629 (2019).
  • Zhu, R., Xue, X., Shen, M., Tsai, Y., Keng, P. C., Chen, Y., … Chen, Y. "NFκB and TNFα as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer" Experimental Cell Research 374(1):181–188 (2019). DOI: 10.1016/j.yexcr.2018.11.022.
This product has no review yet.
Other LCA3 Products
LCA3 Human

LCA3 Lentiviral Vector
LCA3 AAV Vector
LCA3 Adenovirus Vector
LCA3 Protein Vector
LCA3 ORF Vector
LCA3 siRNA Vector
LCA3 miRNA Vector
LCA3 3'UTR Vector
LCA3 CRISPR Knockout Vector
LCA3 CRISPR Activation Vector
LCA3 Control Vectors & Viruses Vector
LCA3 circRNA Vector
LCA3 Internal Vector